KilgourMD Hair Loss System Shows Rapid Results in Menopausal Women Clinical Trial
核心洞察
KilgourMD (搜索)'s Phase II clinical trial demonstrated that 53% of menopausal women with androgenetic alopecia (搜索) achieved meaningful hair regrowth within four months.
The study showed a 60% reduction in hair shedding by month four, with improvements comparable to conventional therapies like minoxidil and finasteride.
Results were validated through objective dermatologist evaluations rather than consumer perception studies, setting new standards for hair loss research.
KilgourMD (搜索), a dermatologist-founded hair growth company, has announced positive results from a four-month Phase II clinical trial evaluating its hair loss treatment system in 43 menopausal women with androgenetic alopecia (搜索). The study represents a significant development in addressing hair loss in an underserved population that has been historically excluded from rigorous hair loss research.
Clinical Trial Design and Methodology
The independent clinical trial evaluated the KilgourMD System (搜索), composed of Prevention and Treatment Serums, in menopausal-aged women experiencing clinically significant levels of hair loss. Unlike many cosmetic studies that rely on consumer perception, this trial employed objective, dermatologist-evaluated outcome measures to ensure scientific rigor.
Regrowth outcomes were assessed by two independent board-certified dermatologists using high-resolution imaging to confirm visible improvements in hair density and scalp coverage over time. The study required participants to have clinically significant hair loss levels, ensuring results reflected true therapeutic impact rather than marginal improvements.
Primary Efficacy Results
By day 120, the trial demonstrated clinically meaningful hair regrowth across multiple measures. Results showed that 53% of participants achieved at least a half-grade improvement on the modified Female Ludwig scale, a threshold dermatologists consider a meaningful visual change. Additionally, 26% of participants showed a full one-grade improvement on this standardized assessment scale.
Across the entire study population, participants experienced an average 11.1% improvement in Ludwig score within the four-month treatment period. According to the study data, this level of improvement is comparable to, and in some cases exceeds, results typically reported after six to twelve months of conventional pharmaceutical therapies such as minoxidil or finasteride.
Hair Shedding Reduction
The trial also demonstrated significant improvements in hair shedding patterns. Standardized combing and washing assessments revealed a 60% reduction in hair shedding by month four, indicating rapid normalization of the hair growth cycle and improved follicular health.
Early improvements were observed as soon as day 45, when greater than 95% of trial participants demonstrated a decrease from baseline in terminal hair shedding count, as measured by standardized hair washing studies conducted in laboratory settings.
Patient-Reported Outcomes
Consumer-reported outcomes reinforced the clinical findings, with more than 80% of participants reporting noticeable improvements in hair density, health, and overall appearance by the end of the four-month study period.
Clinical Significance for Menopausal Women
Dr. James Kilgour, board-certified dermatologist and founder of KilgourMD (搜索), emphasized the importance of the study population. "Menopausal women have been largely excluded from rigorous hair loss research, despite experiencing some of the most challenging and persistent forms of thinning," Dr. Kilgour stated. "This study validates not only the performance of the KilgourMD System (搜索), but also the importance of designing and testing solutions specifically for this population. These results represent a meaningful step forward in how menopausal hair loss is treated."
Publication and Future Research
The complete study results are currently undergoing peer review and are expected to be published later this year. The company positions these findings as setting a new benchmark for evidence-based hair loss solutions, demonstrating that clinically meaningful regrowth and reduced shedding can be achieved within months rather than years of treatment.